secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2021-07-09T23:59:59+00:00
Accession:  0000921895-21-001834
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Michael Donaldson departs; Duggan interim CFO, Maranian accounting officer
------------------------------------------------------------------------------

- Michael Donaldson departed as CFO effective July 2, 2021.
- Robert W. Duggan (CEO & Executive Chairman) appointed interim principal financial officer.
- Jeffrey R. Maranian (Corporate Controller since Nov 2020) appointed principal accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/form8k12566003_07082021.htm
  HTML page:      https://secwatch.observer/filing/0000921895-21-001834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer